AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study
The study was assessing a combination of how often patients with advanced, heart-related AL amyloidosis were hospitalised for cardiovascular issues, and death from any cause over a period of time, when compared with placebo.
While anselamimab did not achieve statistical significance for the overall population in the study, the therapy showed clinically meaningful improvement in a sub-group of patients, AstraZeneca said, without giving details of that group.
JPMorgan analyst James Gordon said that he expects the study "failure in all comers to be seen as a minor negative," adding that while AstraZeneca did not give details of the subgroup in which anselamimab worked, he believes the drugmaker may pursue regulatory approval there.
AL amyloidosis, also referred to as light chain or primary amyloidosis, leads to deposits of amyloid protein in the body because of defective plasma cells, and diagnosis is often delayed.
All patients in the AstraZeneca study had received standard of care for the plasma defect, and anselamimab or a placebo was given on top of that.
If left untreated, the accumulation of the deposits, particularly in the heart and kidneys, can progressively impair the quality of life causing organ damage and dysfunction, and lead to heart failure.
"Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients," said Marc Dunoyer, CEO of AstraZeneca's rare diseases unit, Alexion, which is developing the treatment.
Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 billion for the therapy, against overall annual sales of upwards of $50 billion.
AstraZeneca said it was evaluating the complete data on anselamimab, adding that it plans to share data with health authorities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
Big Pharma booms despite Trump tariff headache
Britain's two biggest drug makers are expected to reveal a profit surge this week as demand booms despite a looming threat of tariffs from the US. GSK, led by Emma Walmsley, is expected to report profit of £4.4 billion for the first half of this year on Wednesday, up from £2.9 billion the previous year, while sales are expected to inch up to £15.3 billion from £15.2 billion in 2024. AstraZeneca, the largest company on the London Stock Exchange, is forecast to report a half-year profit of £5 billion, which is £1.1 billion more than the year before, with sales expected to have increased 8 per cent to £20.6 billion. The sector is under pressure due to the threat of tariffs from the US, a critical market for both companies. President Donald Trump this month threatened to slap a 200 per cent levy on drug imports as part of an escalation of his trade war. His threats have pushed many firms to begin moving factories to – and making larger investments in – the US to protect themselves from retaliation. Last week, AstraZeneca announced plans to invest £37 billion in the US, which accounts for 42 per cent of its sales. The move has also fuelled fears it could switch its London stock market listing to the US, which would be a hit to the City. GSK suffered a blow in the US last week when American regulators recommended against approving the relaunch of its key blood cancer drug Blenrep, which had been pulled from the country in 2022 due to concerns about its side-effects.
Reuters
20 hours ago
- Reuters
China's Premier Li proposes global AI cooperation organisation
SHANGHAI, July 26 (Reuters) - Chinese Premier Li Qiang proposed on Saturday establishing a world artificial intelligence cooperation organisation, calling on countries to coordinate development and security of the fast-evolving technology. Speaking at the opening of the annual World Artificial Intelligence Conference in Shanghai, Li called AI a new engine for growth but said governance is fragmented and emphasised the need to step up coordination between countries to form a globally recognised framework for AI. The three-day event brings together industry leaders and policymakers at a time of escalating technological competition between China and the U.S., with AI emerging as a key battleground between the world's two largest economies. Washington has imposed export restrictions on advanced technology to China, including AI chips and chipmaking equipment, citing concerns the technology could enhance China's military capabilities. Despite these restrictions, China has continued making AI breakthroughs that have drawn close scrutiny from U.S. officials. Li said AI technologies were rapidly evolving but that there were constraints, such as the lack of high-end computing chips and restrictions on talent exchange. He called for breaking through bottlenecks for open and coordinated innovation.
Reuters
a day ago
- Reuters
Centene posts surprise loss as medical costs surge, shares slump
July 25 (Reuters) - Centene (CNC.N), opens new tab on Friday posted a surprise quarterly loss, in yet another disappointment for investors in the sector that has suffered a series of setbacks due to rising costs in government-backed insurance plans. Shares of the company tumbled 14.5% in premarket trading, dragging down peers Elevance (ELV.N), opens new tab and Molina Healthcare (MOH.N), opens new tab, which have also warned of elevated costs in government-backed insurance plans. The insurance sector has been under strain for the past two years due to rising medical costs. On one hand, insurers are grappling with increased utilization of behavioral health services, home care, and high-cost drugs, while on the other, the expiration of pandemic-era subsidies and Medicaid protections has shifted enrollment toward sicker members, squeezing their margins. Centene, which largely focuses on government-sponsored plans, posted a medical cost ratio (MCR) of 93% for the quarter, well above Wall Street's expectation of 89.3% and a clear sign of pressure across all business lines. "The medical cost ratio for the quarter was surprisingly high and appeared related to all major lines of business, although its individual exchange business was likely the biggest culprit," said Morningstar analyst Julie Utterback. The quarterly loss was largely attributed to a downward revision in expected 2025 risk adjustment revenue, part of the Affordable Care Act's mechanism to balance costs across insurers. The adjustment, combined with rising Medicaid expenditure drove Centene to a second-quarter adjusted loss of $0.16 per share, versus an expected profit of $0.86, according to data compiled by LSEG. "We are disappointed by our second-quarter results, but we have a clear understanding of trends that have impacted performance, and are working with urgency and focus to restore our earnings trajectory," CEO Sarah London said. Centene said it would provide 2025 earnings expectations on the conference call. The company is in the process of requesting premium increases for Obamacare plans for 2026 to reflect a higher proportion of sicker patients who need more medical care, than it previously expected. Centene expects to be able to take corrective pricing actions for 2026 in states that represent a substantial majority of its membership in those plans.
